Jane Street Group LLC raised its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 20.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 316,287 shares of the company's stock after buying an additional 54,039 shares during the period. Jane Street Group LLC owned about 0.46% of Replimune Group worth $3,830,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. Freestone Grove Partners LP acquired a new stake in shares of Replimune Group in the fourth quarter valued at $140,000. Northern Trust Corp increased its holdings in Replimune Group by 7.3% during the 4th quarter. Northern Trust Corp now owns 589,635 shares of the company's stock worth $7,140,000 after purchasing an additional 40,134 shares during the period. The Manufacturers Life Insurance Company raised its position in Replimune Group by 5.3% in the 4th quarter. The Manufacturers Life Insurance Company now owns 194,004 shares of the company's stock valued at $2,349,000 after purchasing an additional 9,796 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Replimune Group by 11.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock valued at $132,761,000 after buying an additional 1,083,633 shares during the period. Finally, Dark Forest Capital Management LP acquired a new position in shares of Replimune Group during the fourth quarter worth about $216,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.
Replimune Group Trading Down 5.7%
Replimune Group stock traded down $0.45 during midday trading on Tuesday, reaching $7.41. The stock had a trading volume of 663,362 shares, compared to its average volume of 899,837. The stock has a market capitalization of $570.68 million, a PE ratio of -2.41 and a beta of 0.68. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The stock's 50-day simple moving average is $9.27 and its 200 day simple moving average is $11.45.
Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). Analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on REPL shares. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. HC Wainwright lifted their price target on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Finally, BMO Capital Markets increased their price objective on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $19.43.
Get Our Latest Analysis on REPL
About Replimune Group
(
Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Featured Articles
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
